Search results for "Teas"

showing 10 items of 619 documents

Patterns of transmitted HIV drug resistance in Europe vary by risk group

2014

BACKGROUND: In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported. METHODS: HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression. RESULTS: From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM…

MaleEpidemiologygenotypeHuman immunodeficiency virus 1HIV InfectionsRNA directed DNA polymerase inhibitorhigh risk patientLogistic regressionSettore MED/42 - Igiene Generale E ApplicataMen who have sex with men0302 clinical medicineImmunodeficiency Virusesmiddle agedstatistics and numerical data10. No inequalitySubstance Abuse Intravenous0303 health sciencesadulttransmissionvirus diseasesvirus transmissionhighly active antiretroviral therapyHIV immunopathogenesis3. Good healthMedical MicrobiologyViral Pathogenshigh risk behaviorMedicineScience & Technology - Other TopicsPOPULATIONShealth programanti human immunodeficiency virus agentUSERSmedicine.medical_specialtyScienceSexual BehaviorImmunologySexually Transmitted Diseasesintravenous drug abuse-Microbiology03 medical and health sciencesAntibiotic resistanceSDG 3 - Good Health and Well-beingHuman immunodeficiency virus infectionproteinase inhibitorHumansProtease InhibitorshumanHeterosexualityMicrobial PathogensseroconversionMedicine and health sciencesScience & TechnologyGenitourinary InfectionsMUTATIONSVirologymajor clinical studyLogistic Modelstransmitted drug resistance mutationHeterosexualityHIV-1Viral Diseases:Medical sciences: 700::Basic medical dental and veterinary sciences: 710::Medical immunology: 716 [VDP]drug responsemen who have sex with menDrug resistanceClinical immunologygeographyAPPEARANCEmale homosexualityMedizinische Fakultätimmune system diseasesEpidemiologyINFECTIONMedicine and Health Sciencessubstance abuse030212 general & internal medicineriskMultidisciplinaryACTIVE ANTIRETROVIRAL THERAPYTransmission (medicine)virus mutationQRarticleObstetrics and GynecologyHIV diagnosis and managementMiddle AgedvirologyMultidisciplinary SciencesEuropeInfectious Diseasesfemale:Medisinske fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710::Medisinsk immunologi: 716 [VDP]Reverse Transcriptase InhibitorsHIV clinical manifestationsFemaleepidemiologyblood samplingHIV drug resistanceResearch ArticleAdultRiskrisk-groupAnti-HIV AgentsUrologyprevalenceInfectious Disease Epidemiologysexual behaviorRisk-Takingmaleantiviral resistanceInternal medicineDrug Resistance Viralmedicinecontrolled studyddc:610Homosexuality Male030304 developmental biologydrug resistanceBiology and life sciencesbusiness.industrystatistical modelHIVCD4 lymphocyte countheterosexualitynonnucleoside reverse transcriptase inhibitorHuman immunodeficiency virus 1 infectionDiagnostic medicineINDIVIDUALSdrug effectsWomen's Healthbusinesstrend study
researchProduct

Gelatinases and their tissue inhibitors in a group of subjects with metabolic syndrome.

2013

Aim To evaluate matrix metalloproteases (MMP)-2 and MMP-9 and tissue inhibitor of metalloproteases (TIMP)-1 and TIMP-2 in a group of subjects with metabolic syndrome (MS) subdivided according to the presence or absence of diabetes mellitus. Methods We examined in 90 subjects (51 men and 39 women) with MS, defined following the International Diabetes Federation criteria, and subsequently subdivided into diabetic subjects (22 men and 11 women) and nondiabetic subjects s (29 men and 28 women), the plasma concentrations of MMP-2 and MMP-9 and of TIMP-1 and TIMP-2 using specific enzyme-linked immunosorbent assay kits. Results We found a significant increase in plasma concentrations of MMP-2, MMP…

MaleGelatinasesmedicine.medical_specialtyMatrix metalloproteinase insulin resistanceMatrix metalloproteinaseBiologyMatrix Metalloproteinase InhibitorsGeneral Biochemistry Genetics and Molecular BiologyDiabetes mellitusInternal medicinemedicineMatrix metalloproteasesHumansInternational diabetes federationMetabolic SyndromeMetalloproteinaseTissue Inhibitor of Metalloproteinase-2Tissue Inhibitor of Metalloproteinase-1General MedicineMiddle Agedmedicine.diseaseEndocrinologyMatrix Metalloproteinase 9GelatinasesPlasma concentrationMatrix Metalloproteinase 2FemaleMetabolic syndromeBiomarkersJournal of investigative medicine : the official publication of the American Federation for Clinical Research
researchProduct

Transmission of drug-resistant HIV-1 in Europe remains limited to single classes

2008

BACKGROUND: The spread of drug-resistant HIV-1 might compromise the future success of current first-line regimens. OBJECTIVE: To analyse the extent and impact of transmission of drug-resistant HIV-1 variants in Europe. DESIGN AND METHODS: The European prospective programme (SPREAD) collected demographic, clinical and virological data from 1245 HIV-1-infected individuals in 17 countries diagnosed in 2002-2003. The potential impact of transmitted drug resistance mutations (TDRMs) on therapy response was determined by using genotypic interpretation algorithms. RESULTS: The overall prevalence of viruses with drug-resistance mutations was 9.1% [96/1050; 95% confidence interval: 7.5-11.1]. The ma…

MaleGenes Viralmedicine.medical_treatmentResistanceHuman immunodeficiency virus (HIV)hiv-1HIV InfectionsDrug resistanceSettore MED/42 - Igiene Generale E Applicatamedicine.disease_causeNucleoside Reverse Transcriptase InhibitorGenotypePrevalenceImmunology and AllergyHIV InfectionIsraelriskimmunodeficiency-virus type-1Transmission (medicine)transmissionpersistenceMiddle AgedReverse Transcriptase InhibitorEuropeInfectious Diseasesprimary infectionReverse Transcriptase InhibitorsFemaleeuropeHumanAdultRiskGenotypeLogistic ModelprevalenceImmunologyBiologyresistanceSDG 3 - Good Health and Well-beingDrug Resistance ViralDisease Transmission InfectiousmedicineHumansTransmissionHIV Protease Inhibitortime trendstherapyChi-Square DistributionProteaseHIV Protease InhibitorsloadmutationsVirologyConfidence intervalReverse transcriptaseLogistic ModelsDisease Transmission InfectiouMutationHIV-1AIDS
researchProduct

No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy

2011

An investigation was undertaken to determine whether specific pol mutations hinder long-term immune recovery regardless of virological response. In total, 826 patients with >50 HIV RNA copies/ml, who underwent genotypic resistance testing between 1 January 2000 and 31 December 2003 after >3 years of antiretroviral treatment, and were followed up for >3 years after genotypic resistance testing, were analyzed retrospectively. The outcome of the study was the lack of immune recovery after >3 years of follow-up, defined as a slope by linear regression 50 copies/ml divided by the number of HIV RNA measurements during follow-up. Logistic regression was used for univariable and multivariable analy…

MaleHIV InfectionsDrug resistanceLogistic regressionResistance to nucleoside reverse transcriptase inhibitorCD4+ T-lymphocyteRetrospective StudieImmunopathologyAntiretroviral Therapy Highly ActiveResistance to non-nucleoside reverse transcriptase inhibitorgeneticsResistance to protease inhibitorHIV Infectionresistance to nucleoside reverse transcriptase inhibitorsViralSidaresistance to protease inhibitorsbiologyReverse-transcriptase inhibitorViral LoadGenes poldrug therapy/immunology/virologyReverse Transcriptase InhibitorInfectious DiseasesTreatment Outcomeresistance to non-nucleoside reverse transcriptase inhibitorsReverse Transcriptase InhibitorsFemaleViral loadmedicine.drugHumanpolAnti-HIV AgentsAntiretroviral TherapyViremiaInfectious DiseaseSettore MED/17 - MALATTIE INFETTIVEpharmacology/therapeutic useAcquired immunodeficiency syndrome (AIDS)VirologyDrug Resistance ViralmedicineHumansHighly ActiveRetrospective StudiesAnti-HIV Agents; pharmacology/therapeutic use Antiretroviral Therapy; Highly Active CD4 Lymphocyte Count Drug Resistance; Viral; genetics Female Genes; pol HIV Infections; drug therapy/immunology/virology HIV-1; drug effects/enzymology/genetics Humans Male Mutation Retrospective Studies Reverse Transcriptase Inhibitors; therapeutic use Treatment Outcome Viral Loaddrug resistanceAnti-HIV Agentbiology.organism_classificationmedicine.diseaseVirologyCD4 Lymphocyte CountGenesdrug effects/enzymology/geneticstherapeutic useMutationCD4+ T-lymphocytesHIV-1
researchProduct

H-ficolin (ficolin-3) concentrations and FCN3 gene polymorphism in neonates

2011

Serum H-ficolin (ficolin-3) concentrations (n=613) and FCN3 genotypes (n=529) from a large group of neonates are presented. Both pre-term deliveries and low birthweight (independently of gestational age) were significantly associated with low H-ficolin concentrations but not with heterozygosity for the FCN3 1637delC frameshift mutation. The presence of the variant allele, however, apparently influenced the protein level. No association of FCN3 gene heterozygosity or relative functional H-ficolin insufficiency (determined as serum level ≤8.6 μg/ml) with perinatal infections was found. One premature newborn, with confirmed infection caused by Streptococcus agalactiae, was H-ficolin-deficient …

MaleHeterozygotemedicine.medical_specialtyGenotypeImmunologyGestational AgeBiologymedicine.disease_causeMannose-Binding LectinStreptococcus agalactiaeFrameshift mutationLoss of heterozygosityPolymorphism (computer science)LectinsStreptococcal InfectionsInternal medicineGenotypemedicineHumansImmunology and AllergyFrameshift MutationAllelesGlycoproteinsMannan-binding lectinPolymorphism GeneticHomozygoteInfant NewbornHematologyInfant Low Birth WeightEndocrinologyStreptococcus agalactiaeMannose-Binding Protein-Associated Serine ProteasesImmunologyPremature BirthFemaleGene polymorphismFicolinImmunobiology
researchProduct

Pancreatic digestive hydrolase activities in growing rats fed alternately on raw and heated soya-bean flour.

1994

The time-course effects of two diets containing raw (RSF) or heated (HSF) soya-bean flour on the digestive enzyme levels in the pancreas and in pancreatic juice were investigated in growing rats fed, alternately, on RSF or HSF diets for two 4-week periods. These values were compared with those obtained in a control group fed on a casein diet. RSF and HSF diets lowered N balance (84.8 (SE 0.9), 82.6 (SE 0.8) and 79.9 (SE 0.8) % with control, HSF and RSF diets respectively, at the third week). However, they increased protease activities compared with the control diet (3-fold for trypsin (EC3.4.21.4) and chymotrypsin (EC3.4.21.1) activities in pancreas contents and outputs with the RSF diet; 2…

MaleHot TemperatureTime FactorsHydrolasesNitrogenmedicine.medical_treatmentMedicine (miscellaneous)ColipasePancreatic JuiceCaseinmedicineAnimalsChymotrypsinTrypsinFood scienceColipasesLipaseRats WistarPancreasNutrition and DieteticsProteaseChymotrypsinbiologyChemistryLipaseTrypsinRatsDigestive enzymePancreatic juicebiology.proteinSoybeansmedicine.drugThe British journal of nutrition
researchProduct

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

2016

Transmitted human immunodeficiency virus drug resistance in Europe is stable at around 8%. The impact of baseline mutation patterns on susceptibility to antiretroviral drugs should be addressed using clinical guidelines. The impact on baseline susceptibility is largest for nonnucleoside reverse transcriptase inhibitors.

MaleHuman immunodeficiency virus 1EtravirineRNA directed DNA polymerase inhibitordarunavirHIV InfectionsSettore MED/42 - Igiene Generale E Applicata:Disciplines and Occupations::Health Occupations::Medicine::Public Health [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Salud públicageneticsInhibidores de proteasas:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings]atazanavirmedia_commontransmission:Geographicals::Geographic Locations::Europe [Medical Subject Headings]3. Good healthmicrobial sensitivity testpriority journalEurope ; HIV-1 ; antiretroviral therapy ; drug resistance ; transmissionHIV/AIDSlamivudineReverse Transcriptase Inhibitors/pharmacologyanti human immunodeficiency virus agentDrugMicrobiology (medical)medicine.medical_specialtyantiviral susceptibility:Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation [Medical Subject Headings]media_common.quotation_subjectantiretroviral therapy030106 microbiologyHIV Infections/drug therapy:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Reverse Transcriptase Inhibitors [Medical Subject Headings]Microbial Sensitivity TestsRILPIVIRINEArticleEFAVIRENZ03 medical and health sciencestransmitted drug resistanceSDG 3 - Good Health and Well-beingHumansTransmissionhuman:Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistance [Medical Subject Headings]REVERSE-TRANSCRIPTASE INHIBITORSRilpivirinaINTEGRASEMUTATIONSabacavirmajor clinical studyVirologyInfecciones por VIHRegimenAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Medicine (all); Microbiology (medical); Infectious DiseaseschemistryDrug resistance:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Oxazines::Benzoxazines [Medical Subject Headings]MutationHIV-10301 basic medicinenevirapineDrug resistanceCommunicable diseases:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Confidence Intervals [Medical Subject Headings]chemistry.chemical_compoundantiviral therapyINFECTIONMedicine and Health SciencesPrevalence:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [Medical Subject Headings]ViralNon-U.S. Gov'tReverse-transcriptase inhibitorantiretrovirus agentResearch Support Non-U.S. Gov'tMedicine (all)Human immunodeficiency virus infected patientMiddle AgedvirologyPREVALENCEAntiretroviral therapyEncuestas y CuestionariosANTIRETROVIRAL TREATMENTEuropeInfectious DiseasesHIV-1/drug effectsHIV Protease Inhibitors/pharmacologyRilpivirineReverse Transcriptase Inhibitors:Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections [Medical Subject Headings]FemaleHIV drug resistancemedicine.drugAdultHuman immunodeficiency virus proteinase inhibitor:Chemicals and Drugs::Organic Chemicals::Nitriles::Rilpivirine [Medical Subject Headings]EfavirenzAnti-HIV AgentsResearch SupportResistencia a medicamentosSettore MED/17 - MALATTIE INFETTIVEantiviral resistanceInternal medicineAnti-HIV Agents/pharmacologyDrug Resistance ViralJournal Articlemedicine:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors [Medical Subject Headings]abacavir plus lamivudineEuropa (Continente)Antiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Adult; Anti-HIV Agents; Drug Resistance Viral; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Prevalence; Reverse Transcriptase Inhibitors; Microbiology (medical); Infectious DiseasesemtricitabinenonhumanIntervalos de confianzadrug resistanceMutaciónAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmissionbusiness.industryHIVpredictionInhibidores de la transcriptasa inversaHIV Protease InhibitorsHuman immunodeficiency virus 1 infectiontenofovirINDIVIDUALSDrug Resistance Viral/geneticsBenzoxazinasETRAVIRINEdrug effects3121 General medicine internal medicine and other clinical medicinePrevalenciabusiness
researchProduct

Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin

2019

AbstractCarfilzomib (Cfz), an irreversible proteasome inhibitor licensed for relapsed/refractory myeloma, is associated with cardiotoxicity in humans. We sought to establish the optimal protocol of Cfz-induced cardiac dysfunction, to investigate the underlying molecular-signaling and, based on the findings, to evaluate the cardioprotective potency of metformin (Met). Mice were randomized into protocols 1 and 2 (control and Cfz for 1 and 2 consecutive days, respectively); protocols 3 and 4 (control and alternate doses of Cfz for 6 and 14 days, respectively); protocols 5A and 5B (control and Cfz, intermittent doses on days 0, 1 [5A] and 0, 1, 7, and 8 [5B] for 13 days); protocols 6A and 6B (p…

MaleImmunologymTORC1AMP-Activated Protein Kinases030204 cardiovascular system & hematologyPharmacologyBiochemistryMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineAnimalsHypoglycemic AgentsProtein Phosphatase 2Protein kinase BCardiotoxicitybiologybusiness.industryBortezomibCell BiologyHematologyCarfilzomibCardiotoxicityMetforminMetforminMice Inbred C57BLNitric oxide synthasechemistry030220 oncology & carcinogenesisProteasome inhibitorbiology.proteinbusinessOligopeptidesSignal Transductionmedicine.drugBlood
researchProduct

Conditions for the Enhancing Effect of Protease Inhibitors on the Concanavalin A Induced Thymidine Response of Murine Lymphocytes

1983

Incorporation of [<sup>3</sup>H]-thymidine – [<sup>3</sup>H]-TdR – into concanavalin A (Con A) stimulated murine splenocytes and thymocytes was found to be enhanced by addition of certain concentrations of phenyl-methyl-sulfonylfluoride (PMSF), di-isopropylfluorophosphate (DFP), N-α-tosyl-<i>L</i>-lysyl-<i>L</i>-chloromethylketone (TLCK), and soybean trypsin inhibitor (SBTI). No enhancement could be observed when mononuclear cells of the peripheral blood were used, and a medium enhancement when thymocytes were applied. Furthermore, no enhancing effect of the protease inhibitors (PI) on the Con A response of murine splenocytes could be observed…

MaleIsoflurophateTime Factorsmedicine.medical_treatmentImmunologyBiologyLymphocyte ActivationTosyllysine Chloromethyl KetoneMicechemistry.chemical_compoundPhagocytosisConcanavalin AmedicineAnimalsImmunology and AllergyProtease InhibitorsMice Inbred BALB CProteaseDose-Response Relationship DrugMurine splenocytesDrug SynergismGeneral MedicineMolecular biologyKineticschemistryBiochemistryConcanavalin AImmunologybiology.proteinThymidineSpleenThymidineInternational Archives of Allergy and Immunology
researchProduct

Low Rate of Virological Failure and Maintenance of Susceptibility to HIV-1 Protease Inhibitors with First-Line Lopinavir/Ritonavir-Based Antiretrovir…

2010

Protease inhibitor (PI)-resistant HIV-1 has hardly ever been detected at failed boosted PI-based first-line antiretroviral regimens in clinical trials. However, this phenomenon has not been investigated in clinical practice. To address this gap, data from patients starting a first-line lopinavir/ritonavir (LPV/rtv)-based therapy with available baseline HIV-1 RNA load, a viral genotype and follow-up viral load after 3 and 6 months of treatment were extracted from the Italian Antiretroviral Resistance Cohort Analysis (ARCA) observational database. Based on survival analysis, 39 (7.1%) and 43 (7.8%) of the 548 examined patient cases had an HIV-1 RNA >500 and >50 copies/ml, respectively, after …

MaleLopinavir/ritonavirHIV Infectionsboosted protease inhibitorLopinavirCohort Studies0302 clinical medicineAntiretroviral Therapy Highly Activevirologic failureHIV InfectionTreatment Failure030212 general & internal medicinePyrimidinone0303 health scienceseducation.field_of_studylopinavir/ritonavirLopinavirViral LoadResistance mutationfirst-line antiretroviral therapyReverse Transcriptase Inhibitor3. Good healthTreatment OutcomeInfectious DiseasesRNA ViralReverse Transcriptase InhibitorsMedicineDrug Therapy CombinationFemaleSurvival AnalysiViral loadHumanmedicine.drugAnti-HIV AgentsPopulationPyrimidinones.Settore MED/17 - MALATTIE INFETTIVEEmtricitabinehuman immunodeficiency virus type 103 medical and health sciencesVirologyDrug Resistance Viralantiretroviral drug resistancemedicineHumansProtease inhibitor (pharmacology)educationHIV Protease InhibitorRitonavir030306 microbiologybusiness.industryAnti-HIV AgentHIV Protease InhibitorsSurvival AnalysisVirologyHIV-1RitonavirCohort Studiebusiness
researchProduct